Wafik S. El‐Deiry

American Cancer Society — United States

Medicine · Health Sciences

120h-index87.1kcitations1.5kworks2.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer-related Molecular Pathways(378), Cell death mechanisms and regulation(215), Cancer Research and Treatments(179), Cancer, Hypoxia, and Metabolism(174), Cancer Genomics and Diagnostics(126)

Publications1.5k total

Figure 2 from BrUOG360: A Phase Ib/II Study of Copanlisib in Combination with Rucaparib in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
2025Open Access
Figure 1 from BrUOG360: A Phase Ib/II Study of Copanlisib in Combination with Rucaparib in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
2025Open Access
Table 1 from BrUOG360: A Phase Ib/II Study of Copanlisib in Combination with Rucaparib in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
2025Open Access
Table 2 from BrUOG360: A Phase Ib/II Study of Copanlisib in Combination with Rucaparib in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
2025Open Access
Data from BrUOG360: A Phase Ib/II Study of Copanlisib in Combination with Rucaparib in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
2025Open Access
Table 3 from BrUOG360: A Phase Ib/II Study of Copanlisib in Combination with Rucaparib in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
2025Open Access
Supplementary Table S2 from BrUOG360: A Phase Ib/II Study of Copanlisib in Combination with Rucaparib in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
2025Open Access
Supplementary Table S1 from BrUOG360: A Phase Ib/II Study of Copanlisib in Combination with Rucaparib in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
2025Open Access
Cellular senescence: A novel mechanism of therapeutic resistance in prostate cancer
Cancer Treatment Reviews·2025
Corrigendum to “P53-independent partial restoration of the p53 pathway in tumors with mutated p53 through ATF4 transcriptional modulation by ERK1/2 and CDK9” [Neoplasia, volume 23 (2021) 304325]
Neoplasia·2025Open Access
The evolving landscape of antibody-drug conjugates (ADCs) for treatment of prostate cancer
npj Precision Oncology·2025· 3 citedOpen Access
BrUOG360: A Phase Ib/II Study of Copanlisib in Combination with Rucaparib in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Cancer Research Communications·2025Open Access
DDDR-15. miR-181d as a master-regulatory microRNA in glioblastomas that regulates RAD51 and MGMT expression to mediate acquired temozolomide resistance and cross-resistance to ionizing radiation
Neuro-Oncology·2025Open Access
DNAR-04. Variance in Methyl-guanine methyl transferase (MGMT) expression as a defining feature of intra-tumoral heterogeneity that contribute to acquired temozolomide resistance in glioblastoma
Neuro-Oncology·2025Open Access
DDEL-32. An atlas of ex vivo drug sensitivity profiles in 666 clinical glioblastoma samples revealed distinct survival-associated networks
Neuro-Oncology·2025
DNAR-03. ONC201 synergizes with concurrent temozolomide-radiotherapy against newly diagnosed glioblastomas
Neuro-Oncology·2025Open Access
913 Reprogramming the tumor immune microenvironment: STING activation synergies with BRAF inhibition to boost NK-mediated cytotoxicity in BRAF V600E mutant melanoma
Regular and Young Investigator Award Abstracts·2025Open Access
IMMU-21. Antiviral Therapy Reverses CMV-Induced Oncogenic Signaling and Enhances NK Cell Cytotoxicity in Glioblastoma with Associated PD-L1 Upregulation and Immune Modulation
Neuro-Oncology·2025Open Access
DDEL-24. Investigating GSK3 Inhibition as a Strategy to Modulate the Blood-Brain Barrier and Enhance Drug Uptake in Pediatric Diffuse High-Grade Glioma Models
Neuro-Oncology·2025Open Access
Feedforward miR-181d degradation modulates population variance of methyl-guanine methyl transferase and temozolomide resistance
Cell Reports·2025Open Access
page 1 of 75Next →

Frequent Co-authors

Mikhail V. Blagosklonny(8), John Abrams(6), Emad S. Alnemri(6), Eric H. Baehrecke(6), Michael O. Hengartner(6), Walter Malorni(6), Lorenzo Galluzzi(5), Ilio Vitale(5), Douglas R. Green(5), Richard A. Knight(5), Sharad Kumar(5), Stuart A. Lipton(5), Peter Vandenabeele(5), Marcus E. Peter(5), Gen Sheng Wu(5), Stuart A. Aaronson(4), David W. Andrews(4), Nicolás G. Bazán(4), Klas Blomgren(4), Christoph Borner(4)